US20070257066A1 - Pbod System - Google Patents

Abstract

The present disclosure includes several pioneering discoveries. Including, a complete dose (10) of gas (60) formed essentially by motive gas (65). Dose (10) having the form of a plurality of bubbles (75). Also, a pbod ejected from any selected initial velocity. Also, a succession of identical bubbles formed essentially by a motive gas. Pbod systems transport a dose of liquid and a dose of gas to a target via pbod (70). Pbod systems may provide a solution to many various problems in many various technologies.

Description

TECHNICAL FIELD OF THE INVENTION
• The present pioneering discovery resides in pbod systems. A pbod consists essentially of: a dose of liquid having the form of one ball; and a dose of gas having the form of a plurality of balls (bubbles); and the ball of liquid encloses the balls of gas; and the pbod is assembled on demand.
• Portions of the present description are previously disclosed in COFFELT, JR. U.S. patent application Ser. No. 10/827,901 filed 19 Apr. 2004 (19.04.04).
• Pbod systems are capable of providing a solution to numerous problems. Obviously, there are many pertinent problems in many various technologies, which are incorporated herein by reference. The pbod may be used in any of these pertinent arts. The following are examples of these pertinent arts and problems.
• The art of forming pendant drops is well known. And further, there are many arts, which utilize the pendant drop, or droplet. For example, fuel injection, surgery, chemical/biological arts, or eye drops, including many others. And within these arts, a typical range of quantities is in the microliter range. For example, an over-the-counter pendant eye drop is between 15 to 30 microliters. It is also well known, an optimal quantity of liquid for opthalmic medicament applications is in the 5 to 7 microliter range. For example, TIMOLOL (Bausch & Lomb, Rochester, N.Y., U.S.). And in light of the high cost of opthalmic medicament, a 3 microliter dose is most likely highly desirable. The prior art clearly shows the art of forming one pendant drop on demand is not capable of reliably attaining these small microliter quantities.
• It is also well known, an additional problem has existed for many years in the prior eye drop systems. Specifically, the requirement of tilting the head back to instill an eye drop. One method, which attempts to solve this problem is dispensing the medicament in a spray (plurality of droplets). However, these jet systems are clearly subject to inaccuracies, recalibration, and failures due to the presence of complex moving parts and substantial frictional forces.
• Additional prior methods attempt to solve this problem (tilted head). For example, in Basilice, et al U.S. Pat. No. 5,848,999 Dispensing eye drops is disclosed. The methods of Basilice attempt to solve this problem by utilizing an apparatus designed to dispense the eye drop on the lower eye-lid. However, this method includes an abnormal displacement of the lower eye-lid. Therefore, the systems of Basilice are clearly not optimal.
• Examples of complex dispensing apparatus include, Cohen et al U.S. Pat. No. RE 38,007 discloses a microdispensing opthalmic pump. The systems of Cohen inescapably dispense a plurality of droplets. The systems in Cohen are required to contain several complex moving parts. Where this complex prior system includes springs, balls, moving pistons, and check valves. Therefore, the systems of Cohen are subject to failure, error, repair, or recalibration due to the inescapable inherent frictional forces present in the system.
• Further example of complex prior systems include Ershow et al U.S. Pat. No. 5,756,050 discloses a device for dispensing microdoses (microdrops/drops). For example, BIOMEK.RTM.1000 (BECKMAN) Automated Laboratory Workstation for dispensing cell lines and bacteria.
• Further attempts to solve these pertinent problems are disclosed in Coffelt, Jr. U.S. Pat. No. 6,206,297 gasdrop and apparatus for manufacturing gasdrop. The accuracy of dosages in the gasdrop, in the microliter range, is unknown.
• Excessive fuel emissions is also a well known problem. The emissions of combustion engines clearly must be reduced to a minimum. And it is obvious, if the same quantity of power can be produced from less fuel, the emissions will most likely be less.
• Pbod systems is a pioneering technology. This technology is disclosed in Coffelt, Jr. International Publication No. WO 02/43845, published under the Patent Cooperation Treaty 6 Jun. 2002, Dual microliter dosage system. In WO 02/43845, the terms “dosdrop” and “microdose” refer to the article of manufacture in the present specification. And in the corresponding U.S. patent application Ser. No. 10/296,487, filed 22 Nov. 2002, the term “dosdrop” is changed to “pbod” or “hbod”. This name change does not alter the structure disclosed in WO 02/43845. This change merely changes the name associated with the structure.
• To make clear, the presently disclosed novel pbod systems manufacture the structure disclosed in WO 02/43845. For example, a “pbod” is a “dosdrop”; and a “pbod” is a “microdose” where each of these terms refer to the same structure. And the objective of these changes in name is to attain the most suitable name for this pioneering article of manufacture.
• The term “pbod” refers to “plural body on demand”. A pbod consists essentially of: a dose of liquid having the form of one first ball; and a dose of gas having the form of a plurality of balls (bubbles); and the ball of liquid encloses the balls of gas; and the pbod is assembled on demand. And the pbod is ejected from the system on demand.
• The prior pbod systems in WO 02/43845 utilize distinct discrete complex metering apparatus, first, to inject a dose of liquid into the flow channel; and second, insert a syringe needle into the dose of liquid; and third, inject a dose of gas into the liquid via the needle. The dose of gas is formed by inserting the needle into the liquid; and displacing the plunger of the syringe.
• Subsequently, a motive gas ejects this dose of liquid and dose of gas having the form of one pbod. Where this motive gas may form a portion of the dose of gas. However the prior art motive gas does NOT form the complete dose of gas. The prior art does not contemplate any method or or apparatus to attain the results of the present invention.
• Problems in these prior art pbod systems include the requirement of complex metering apparatus. Which inherently creates a relatively high probability for error and reduced reliability. It is well known, systems with moving parts are subject to error and failure due to frictional forces. And therefore, these complex pbod systems are subject to recalibration or repair. Further, the cost of manufacturing these prior pbod systems is relatively excessive.
• Additional problems in the prior pbod systems include the problems associated with dispensing small microliter bubbles into a liquid. For example, experiments show, under normal conditions of the systems in WO 02/43845, the probability of ejecting a limited plurality of 0.07 microliter bubbles on demand from a syringe needle is very near zero. Therefore, this problem imposes quantitive limitations on the prior art pbod systems.
• Additional problems in this prior art pbod system include, the system is not optimal to be used in a doctor-patient environment. And further, this prior art pbod system is not optimal for a person to self-instill a pbod to the eye. For example, a pbod dispensed on the eye for dryness relief.
INDUSTRIAL APPLICABILITY
• In light of all of the above-mentioned problems in the prior art pbod systems, and the numerous well known problems and failed attempts in all pertinent technologies, there is clearly a need for a simple inexpensive system, which will reliably dispense optimal doses of liquid on demand to a target. For example, it is well known, there are numerous attempts over a period of many years, which have failed to dispense small microliter doses in a unitary body. For example, the pendant drop.
• Therefore, the present pioneering discovery will be greatly appreciated for providing simple, reliable pbod systems, which transport a unitary body of liquid and gas to a target. Where optimal accurate doses of liquid and gas are attainable. Further, provide a pbod system which is capable of allowing the doses to vary over a range of quantities IF desired. Further, provide a pbod system capable of being adapted to be used, for example, in a doctor-patient or self-instill environment; and possibly chemical/biological environment, for example, pipette systems; fuel injection environment, including many other technologies, which rely on this type of fluid and/or gas transportation. The present pioneering discovery will be greatly appreciated for providing reliable pbod systems, which may provide a solution to problems in many various technologies.
SUMMARY OF THE INVENTION
• The present pioneering discovery resides in pbod systems. A pbod consists essentially of: a dose of liquid having the form of one first ball; and a dose of gas having the form of a plurality of balls (bubbles); and the ball of liquid encloses the balls of gas; and these components of the pbod are assembled on demand. For example, first, the ball of liquid is disjointed from the gas; and second, the ball of liquid encloses the gas.
• A novel pbod system resides in a pbod system where a complete dose of gas is formed essentially by a motive gas. Where this motive gas is the sole source of this complete dose of gas. And this dose of gas is subsequently the complete dose of gas in one pbod.
• The present disclosure includes a second discovery. Where this second discovery is summarized as a pbod capable of being dispensed from any indiscriminate selected initial velocity. For example, a pbod having an initial velocity, which is either vertical, horizontal, or any other selected orientation.
• The present disclosure includes a third discovery. This third discovery is summarized as a succession of identical bubbles formed essentially by a motive gas. Where the spacing of these bubbles appears to be nearly identical. Further, the diameter of these identical bubbles is inversely proportional to the flow speed. For example, a greater flow speed forms smaller bubbles. (i.e. 0.003 cm or 0.03 cm dia.)
• The present disclosure includes a fourth discovery. This fourth discovery is summarized as a pbod system, which utilizes inherent residual liquid in a discharge tube. This system ejects a pbod from the discharge tube; and a dose of liquid inherently remains in the discharge tube; and this residual liquid inherently forms a plurality of transverse walls; and this residual liquid is used in conjunction with an additional dose of liquid to form a subsequent pbod. For example, a 3 ul dose of liquid is added to 1 ul residual liquid to form a 3 ul pbod.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING
• The present invention is further described by reference to the appended drawings taken in conjunction with the following description wherein identical or corresponding parts are identified by the same reference character throughout the several views of the drawing where:
• FIG. 1 is a right side perspective sectional view of a pbod dispenser, including: a flexible bottle (40); a dispensing tip (100A); a liquid (50); gas (60); and a pbod (70).
• FIG. 2 is a right side sectional view of pbod dispensing tip (100A); and bottle (40).
• FIG. 3 is a top view of pbod dispensing tip (100A).
• FIG. 4 is a right side view of structure (22).
• FIG. 5 is a right side sectional view of pbod dispensing tip (100A); and the axis of tube (27) is horizontal.
• FIG. 6 is a right side sectional view of pbod dispensing tip (100A); and tip (100A) contains a dose (77) of liquid (50).
• FIG. 7 is a right side sectional view of pbod dispensing tip (100A); and tip (100A) contains the dose (77); and dose (77) encloses a dose (10) of gas (60); and dose (10) having the form of a plurality of balls (bubbles).
• FIG. 8 is a front sectional view of a prototype R22; and a succession of identical bubbles (204).
• FIG. 9 is a front view of a prototype R11; and a pbod (70).
• NOTE: the diameter of pbod dispensing tip (100A) is exagerated in FIG. 1 and FIG. 2 to show detail.
• NOTE: FIG. 1 does not show resin (5) for clarity; and FIG. 1 does not show resin (1) for clarity.
• NOTE: FIG. 2 does not show portions of cap (45) for clarity; and does not show portions of cap (41) for clarity.
• NOTE: FIG. 5 does not show portions of tube (43) for clarity; and a single line is utilized to represent tube (43).
DETAILED DESCRIPTION OF THE INVENTION
• The present pioneering discovery resides in pbod systems. Including, a pbod system where a complete dose of gas is formed essentially by a motive gas. Where this dose of gas is the complete dose of gas in one pbod.
• The pbod is referred to as a “microdose” in the International Application published under the Patent Cooperation Treaty under No. WO 02/43845, 6 Jun. 2002 (06.06.02), Dual Microliter Dosage System.
• The structure of the microdose in WO 02/43845 is the same structure disclosed in the present specification. Where this structure is presently identified by the term “pbod”. The name is changed to attain the most suitable name for this pioneering article of manufacture.
• A pbod consists essentially of: a dose of liquid having the form of one first ball; and a dose of gas having the form of a plurality of balls (bubbles); and the ball of liquid encloses the balls of gas; and these components of the pbod are assembled on demand. For example, first, the liquid is disjointed from the gas, and second, the ball of liquid encloses the balls of gas. The pbod is subsequently ejected from the system.
• Each dose, liquid, gas, motive gas, and additional pertinent parameters must be capable to assemble a pbod on demand. If a pbod is formed, it can be concluded, all pertinent parameters are capable to form one pbod.
• A pbod exists in two states. First, a non-discrete pbod attached to a surface. Second, a discrete pbod.
• Objectives of the present invention include, provide a pbod system where a complete dose of gas is formed essentially by a motive gas. Further, provide a pbod system, which is simple, relatively inexpensive, and substantially more reliable over the prior art. Further, provide a pbod system capable of attaining optimal dosages. i.e. opthalmic, fuel-injection, including many others. Further, provide a pbod system, which is not subject to substantial frictional forces, recalibration, or mechanical failure due to frictional forces. i.e. moving pistons.
• A second discovery includes a pbod capable of being dispensed from any indiscriminate selected initial velocity. For example, a pbod having an initial velocity, which is either vertical, horizontal, or any other selected orientation.
• A third discovery includes a succession of identical bubbles formed essentially by a motive gas. Where the spacing of these bubbles appears to be nearly identical. Further, the diameter of these identical bubbles is inversely proportional to the flow speed. For example, a greater flow speed forms smaller bubbles. For example, a flow speed of [x] forms bubbles of 0.03 cm diameter; and a flow speed of [y] forms bubbles of 0.003 cm diameter; where [y] is greater than [x].
• A fourth discovery includes a pbod system, which utilizes inherent residual liquid in a discharge tube. First, this pbod system ejects a pbod from the discharge tube; and second, a dose of liquid inherently remains in the discharge tube; and third, this residual liquid inherently forms a plurality of transverse walls; and this residual liquid is used in conjunction with an additional dose of liquid to form a subsequent pbod. For example, a 3 ul dose of liquid is added to 1 ul residual liquid to form a 3 ul pbod.
• Meaning of TERMS: The present specification contains well known structures having axis of symmetry. Where these structures have a longitudinal axis of symmetry, and a transverse axis of symmetry.
• For example, in a cylindrical shaped tube, the transverse axis of symmetry coincides with a diameter of the tube. And the longitudinal axis of symmetry is a line perpendicular to the diameter and intersecting the mid-point of the diameter.
• The following embodiments are described with reference to the longitudinal axis of symmetry. For example, in FIG. 2 the longitudinal axis of symmetry of tube (27) is vertical.
• The term “axis” as used hereinafter means: “the longitudinal axis of symmetry”.
• The term “transverse” as used hereinafter means: “a direction perpendicular to the longitudinal axis of symmetry”. For example, in FIG. 2, a transverse direction is disposed in a horizontal plane relative to the axis of tube (27). Units of MEASURE: milligrams=mg; microliters=ul centimeters=cm; millimeters mm; milliliters=ml grams=g; cubic centimeters=cc
• The present invention is hereinafter described with reference to the appended drawings where identical or corresponding parts are identified by the same reference character throughout the several views of the drawing.
• The following is a description of general embodiments. And more specific embodiments of the appended figures are provided by the following prototypes.
• FIG. 1 is a right side perspective sectional view of a pbod dispensing tip (100A). Dispensing tip (100A) is symmetrical, therefore, the left side perspective sectional view is a mirror image of FIG. 1.
• The lower end of tip (100A) is a cylindrical shaped tube (27). Tube (27) having a flat annular outlet (25).
• A conical shaped tube (28) is rigidly attached to the upper end of tube (27). The upper end of tube (28) is monolithic with a transverse disc shaped wall. This disc shaped wall having a centrally located opening (35). For example, tube (28), the disc shaped wall, and opening (35) can be a standard VISINE dispensing tip. i.e. over-the-counter eye drops.
• FIG. 2 shows tube (27) is attached to tube (28) by an annular epoxy resin (4). Resin (4) forms a leak-tight seal at this point of attachment.
• FIG. 1 shows the inner diameter surface of tube (27) and the inner diameter surface of tube (28) forms a continuous flow channel. The axis of tube (27) is co-axial with the axis of tube (28).
• There are clearly standard methods to form tube (27) and tube (28) as a unitary body. Therefore, the lower end of tip (100A) does not show the joints and resin (4) in FIG. 1.
• A cylindrical shaped tube (29) is rigidly attached to the upper end of tube (28). This attachment is formed by annular epoxy resin (4). An annular leak-tight seal is formed at this point of attachment. Tube (29) is co-axial with tube (28).
• The lower end of tube (29) is co-planar with the upper end of tube (28).
• A cylindrical shaped tube (11) is rigidly attached to the upper end of tube (29). The upper flat annular surface 5 of tube (11) is co-planar with the upper flat annular surface of tube (29). Tube (11) is attached to tube (29) by annular epoxy resin (2). The boundaries of resin (2) are limited to the lower flat annular surface of tube (11). The boundaries of resin (2) are also limited to the outer surface of tube (29).
• FIG. 2 shows a structure (22) is rigidly attached to the upper end of tube (29). This attachment is formed by epoxy resin (1). Resin (1) is located at two places, one at the lower left side of structure (22), and one at the lower right side of structure (22) (FIG. 2). The boundaries of resin (1) are limited to the outer surface of structure (22). The boundaries of resin (1) are also limited to the width of structure (22) indicated by the dimension “N”. The boundaries of resin (1) are also limited to the upper flat surface of tube (11), and the upper flat surface of tube (29).
• Structure (22) is formed of two flat rectangular converging walls. FIG. 2 and FIG. 4 show structure (22) having an inverted V shape.
• FIG. 3 is a top view of dispensing tip (10A). FIG. 3 does not show resin (1) for clarity. FIG. 3 shows structure (22) is centrally located on tube (11). And the width of structure (22) is indicated by dimension “N”.
• FIG. 4 is a right side view of structure (22). The height of structure (22) is indicated by dimension “V”. And the distance between the lower end of the walls is indicated by dimension “Y”.
• A tube (43) is rigidly attached to the lower portion of tube (27), as shown in FIG. 2. This attachment is formed by an annular epoxy resin (5). Resin (5) provides a leak-tight seal. Outlet (25) is located near the mid-point of the axial length of tube (43). Tube (43) is co-axial with tube (27).
• Tube (43) is rigidly attached to a bottle (40) as shown in FIG. 2. This attachment is formed by an annular epoxy resin (6). Resin (6) forms a leak-tight seal.
• The lower end of tube (43) includes a removeable cap (45), and a removeable seal (44). There are clearly many standard methods to form a cap and seal. For example, the cap and tip on a standard VISINE bottle (eye drop bottle). Bottle (40) also includes a removeable cap (41), and a removeable seal (42).
• FIG. 2 shows bottle (40) contains an appropriate quantity of liquid (50). Where the appropriate quantity of liquid (50) can be determined according to the objectives set forth in the following experiments.
• FIG. 1 depicts a general embodiment of a pbod dispenser. For example, a pbod dispenser used to self-instill a pbod on the eye.
• FIG. 1 shows point S is on the left side vertical wall of bottle (40). And point T is on the right side vertical wall of bottle (40). Where these points S and point T are the typical points used to dispense a 30 ul pendant drop from a standard VISINE eye drop bottle.
• Prototype R29 is similar to FIG. 1. Prototype R29 utilizes a VISINE bottle (40). Where points S and point T are on the vertical side walls of the VISINE bottle (40); and the axis of tube (27) is vertical.
• TO make clear: for prototype R29: the applied collapsing force (at points S and T) is horizontal; and the axis of tube (27) is vertical.
• For prototype R29: dispensing tip (100A) is located near the neck of the VISINE bottle. Where an objective of this location is to avoid damage to the dispensing tip (100A) during collapsing of the bottle walls.
• FIG. 1 shows an appropriate quantity of liquid (50) located in the lower portion of bottle (40). Where the appropriate quantity of liquid (50) can be determined according to the objectives set forth in the following experiments. For example, bottle (40) is rotated such that structure (22) is immersed in liquid (50); and bottle (40) is rotated such that structure (22) is surrounded by gas (60).
• FIG. 1 shows a complete pbod dispensing apparatus. FIG. 1 shows a dynamic state. The pbod dispensing apparatus has ejected a pbod (70). Pbod (70) consists essentially of: a dose (77) of liquid (50) having the form of one first ball; and a dose (10) of gas (60) having the form of a plurality of bubbles (75); and dose (77) encloses dose (10); and dose (77) and dose (10) are assembled on demand.
• This pbod dispensing apparatus shown in FIG. 1 forms a motive gas (65). Where this motive gas (65) is the sole source of the dose (10). Dose (10) is formed essentially by motive gas (65). For example, a syringe needle does not exist in this novel pbod system.
• Pbod (70) contains three bubbles (75). Where this quantity of three bubbles (75) is within the capabilities of the present specification. And these three bubbles (75) form the complete dose (10). For example, dose (10) is 1 ul of gas (60); therefore, the first bubble (75) contains 0.3 ul of gas (60); and the second bubble (75) contains 0.3 ul of gas (60); and the third bubble (75) contains 0.3 ul of gas (60); and each of these three bubbles (75) is formed by motive gas (65). The motive gas (65) forms the three bubbles (75). And these three bubbles (75) form the complete dose (10) of pbod (70).
• Methods to form pbod (70) are provided in the following experiments.
• FIG. 8 shows a front sectional view of a prototype R22. Prototype R22 is formed of a VISINE bottle (200); and a VISINE dispensing tip (201); and a tube (202).
• VISINE tip (201) is located at the typical location on the bottle, which dispenses a 30 ul pendant drop. The VISINE tip (201)is not altered. The VISINE bottle (200) is not altered.
• The upper end of tube (202) is cut to fit into the inner diameter of tip (201). Where these cuts form an inverted conical shape at the upper end of tube (202). Tube (202) is fitted to tip (201) such that a leak-tight seal is formed.
• Prototype R22 is utilized to form a succession of identical bubbles (204). FIG. 8 shows succession (204) is formed of eight bubbles; and each of these bubbles have identical diameters. For example, for a bubble diameter of 0.007 cm, the variance of the diameter is estimated to be within approximately plus or minus 0.002 cm.
• FIG. 8 shows a dynamic state. And also shows a selected quantity of liquid (207) disposed in prototype R22. The upper end of liquid (207) is indicated by the arcuate line at point (211). The concise steps, which form the configuration shown in FIG. 8 are set forth in the following experiment E. FIG. 8 does not show the inherent phenomenon, which causes the succession of identical bubbles (204) to be formed.
• FIG. 8 shows the succession of identical bubbles (204) is located near the axis of tube (202). And liquid (207) encloses bubbles (204).
• Prototype R22 is described further in the following table.
• FIG. 9 shows a front view of a prototype R11. One of the objectives of prototype R11 is to show a very reliable pbod system. For example, prototype R11 dispenses more than three hundred consecutive pbods; and each pbod contains 7 ul of liquid; and there is no overspray for any trial. Where prototype R11 utilizes inherent residual liquid located in the discharge tube.
• FIG. 9 shows the upper end of prototype R11 is a flexible VISINE bottle (300). Where this VISINE bottle does not contain a dispensing tip. The upper end of a tube (301) is rigidly attached to the lower end of the neck of the VISINE bottle (300). Tube (301) is co-axial with the neck of the VISINE bottle. This attachment is formed by an annular epoxy resin (311). Resin (311) forms an annular leak-tight seal.
• The upper end of a tube (302) is inserted approximately 0.5 cm into the lower end of tube (301). The lower end of tube (301) is indicated by reference numeral (310).
• Prototype R11 is utilized to dispense a pbod (70). The scale of FIG. 9 is not suitable to show the interior structure of pbod (70); and therefore, a dot is utilized to show pbod (70).
• Prototype R11 is described further in the following table. A concise method of utilizing prototype R11 is provided in the following Experiment Q.
• The following prototypes are particular embodiments of the appended figures of the drawing. Where the present description of these figures, and the following description in the prototype table define the structure of the prototype. Each prototype table contains a list of the pertinent figures of the drawing. For example, in prototype table PROTOTYPE R29, FIG. 2, FIG. 3, and FIG. 4 define the configuration of prototype R29, and the present description of these figures define the configuration of prototype R29, and the corresponding parts of prototype R29 are further defined in the prototype table PROTOTYPE R29, and prototype R29 is similar to FIG. 1.
• All prototypes presented herein are made by the present Inventor. All prototypes are made by hand. Also, only one prototype of each model No. exists. For example, only one prototype R29 exists.
• All cuts in all prototypes are made with a STANLEY knife (pencil style handle) with blade model No. 11-411 UPC No. 076174114119.
• The cuts are made according to the following steps:
• First, placing one sheet of paper (20 lb) on a rigid solid horizontal wooden table;
• second, placing the part on the sheet of paper;
• third, placing the cutting edge of the blade on the surface of the part; and the cutting edge of the blade resides approximately horizontal; and the cutting edge of the blade remains approximately horizontal throughout the entire cut;
• fourth, slowly increasing the force on the handle in one vertical direction until cutting begins; and maintaining an approximate constant speed throughout the entire cut; and
• maintaining only one vertical direction of cutting throughout the entire cut.
• NOTE: each entire surface is cut with only one continuous motion. For example, while cutting a 0.5 cm diameter tube, the blade traverses a vertical distance of 0.5 cm in one continuous motion.
• The parts of prototype R29 are assembled according to the following steps, including:
• First, cutting all parts to the desired dimension;
• second, inserting a smooth solid copper wire into the outlet end of tube (27), such that the end of the wire extends approximately 0.8 cm beyond the upper end of tube (27); and the OD of the wire matches the ID of tube (27) to a slip-fit (i.e. the OD of the wire is approximately 0.02 cm less than the ID of tube (27);
• third, placing tube (28) on the upper end of tube (27) such that the wire maintains tube (28) co-axial with tube (27);
• fourth, applying the lower portion of annular resin (4) as shown in FIG. 2, and allow to dry for 5 hours;
• fifth, placing tube (29) on tube (28) as shown in FIG. 2; and applying annular resin (4) and allow to dry for 5 hours;
• sixth, placing tube (11) on the upper end of tube (29) as shown in FIG. 2; and applying resin (2) as shown in FIG. 2;
• seventh, placing structure (22) on the upper end of tube (29) and applying resin (1) as shown in FIG. 2;
• eighth, while holding only tube (27), removing the copper wire from tube (27) (objective is to not break seal of resin (4));
• ninth, attaching tube (27) to tube (43) with resin (5) as shown in FIG. 2, and allow to dry for 5 hours;
• tenth, attaching tube (43) to bottle (40) as shown in FIG. 2; and allow to dry for 8 hours; and the axis of tube (27) is perpendicular and co-planar with the axis of the neck of the VISINE bottle (40); and dispensing tip (100A) is located near the neck of the VISINE bottle (40).
• The parts of prototype R29 are placed by hand at the desired location; and the epoxy resin is applied; and the location of the part is adjusted as necessary using a narrow steel rod and magnifying glass (approximately 3 times power). The dimensions of the prototype are checked after drying.
• For prototype R29: structure (22) is formed from one flat sheet of PVC; and first, cut to the desired width; and second, bend to two flat parallel walls; and third, cut to the desired height; and fourth, separate the two walls to the desired dimension Y.
• The present figures of the drawing depict the configuration of the present prototypes. These figures are an approximate scaled version of the actual prototype. Therefore, IF necessary, these figures of the drawing can be utilized to determine the location of a part. Also, parts of the prototypes may be not shown for clarity.
• Obviously, the appended figures of the drawing do not show the inherent results of the above-described method of forming the present prototypes. For example, resultant surface roughness of a cut surface, edge sharpness of a cut surface, or very small gaps between surfaces (i.e. approximately 0.002 cm, or approximately 0.01 cm). All inherent features, which result from the method of making the present prototypes described herein (made by hand) form a part of the present disclosure.

  PROTOTYPE R29

  Prototype R29 is previously described and shown in FIG. 2,

  FIG. 3, FIG. 4, and similar to FIG. 1; and further described

  as follows:

  PART No.	DESCRIPTION
  (22)	converging rectangular flat walls; inverted V
  	shape; transparent PVC; dimension N = 0.13 cm;
  	dimension V = 0.23 cm; dimension Y = 0.10 cm;
  	0.025 cm thick; from the bubble wrap packaging
  	from JB WELD (JB WELD COMPANY)
  	UPC: 043425826558
  (11)	tube; and each end is flat; material: TEFLON;
  	0.317 cm OD; 0.165 cm ID; 0.13 cm axial length;
  	(SPECTRUM CHROMATOGRAPHY)
  (29)	tube; and each end is flat; material: TEFLON;
  	0.158 cm OD; 0.078 cm ID; 0.69 cm axial length;
  	(SPECTRUM CHROMATOGRAPHY)
  (28)	dispensing tip from VISINE; 0.16 cm upper end OD;
  	0.08 cm lower end ID; 0.35 cm axial length;
  	opening (35) is 0.02 cm diameter; from lot No.
  	0103611/expire OCTOBER 2005; material is unknown/
  	similar to polyethelene (PFIZER, INC.);
  	0.04 cm upper end ID UPC: 074300008035
  (27)	tube; and each end is flat; material: TEFLON;
  	0.158 cm OD; 0.078 cm ID; 0.64 cm axial length;
  	(SPECTRUM CHROMATOGRAPHY)
  (1)(2)(4)	JB WELD (JB WELD COMPANY) UPC: 043425826558
  (5)(6)
  (40)	VISINE bottle; 15 ml (PFIZER, INC.)
  (41)	VISINE cap; from 15 ml VISINE bottle(PFIZER, INC)
  (43)	neck of VISINE bottle; 15 ml; approximately
  	0.9 cm ID; 1.3 cm axial length; tube shape
  (42)	VISINE dispensing tip (PFIZER, INC.)
  (44)	annular seal; from portion of VISINE dispensing
  	tip; 1.0 cm OD; 0.9 cm ID; and 0.2 cm length
  	(PFIZER, INC.)
  (45)	VISINE cap; from 15 ml VISINE bottle(PFIZER, INC)
  NOTE:
  resin (1) is 0.1 cm wide; 0.13 length; 0.08 cm height; and is located at two places; and the 0.13 cm length of resin (1) coincides with the dimension N of structure (22).

• PROTOTYPE R22

  Prototype R22 is previously described and shown in FIG. 8;

  and further described as follows:

  PART No.	DESCRIPTION
  (200)	VISINE bottle; empty; 30 ml (PFIZER, INC.)
  (201)	VISINE dispensing tip (PFIZER, INC.)
  (202)	tube; and each end is flat; 0.317 cm OD;
  	0.078 cm ID; 6.5 cm length; polyethelene;
  	translucent; the upper end of tube (202) is
  	cut to accomodate the lower end ID of tip (201)
  	such that a leak-tight seal is formed

• PROTOTYPE R11

  Prototype R11 is previously described and shown is FIG. 9;

  and further described as follows:

  PART No.	DESCRIPTION
  (300)	VISINE bottle only(no tip); 30 ml (PFIZER, INC)
  (302)	tube; and each end is flat; 0.18 cm OD;
  	0.08 cm ID; 3.0 cm length; the upper end OD of
  	tube (302) is cut such that tube (302) can be
  	inserted into tube (301); and such that a leak-
  	tight seal is formed; polyethelene
  (301)	tube; and each end is flat; 0.28 cm OD;
  	0.13 cm ID; 2.0 cm length; polyethelene
  (311)	JB WELD (JB WELD COMPANY) UPC: 043425826558

• The following table is a list of the experiments, the prototype utilized in the experiment, and a summary of an objective of the experiment:

  SUMMARY OF EXPERIMENTS

  EXPERIMENT X:	prototype R29;	measure diameter of liquid on
  		test paper.
  EXPERIMENT U:	prototype R29;	other person executes
  		Experiment X
  EXPERIMENT M:	prototype R29;	measure mass of pbod
  EXPERIMENT Q:	prototype R11;	form pbod utilizing residual
  		liquid; and observe diameter
  		of discrete pbod i.e. FIG. 9
  EXPERIMENT E:	prototype R22;	form succession of identical
  		bubbles
  EXPERIMENT V:	prototype R29;	eject a pbod having a vertical
  		initial velocity i.e. a direction
  		opposite to a gravity vector
  EXPERIMENT H:	prototype R29;	eject a pbod having a horizontal
  		initial velocity
  EXPERIMENT L:	prototype R29;	eject a pbod having a 45 degree
  		initial velocity; and a 135
  		degree initial velocity

  
  Experiment X is executed according to the following steps [Xa.] to [Xg.] as follows:
  [Xa.] Holding bottle (40) in one hand at points S and point T with the thumb and forefinger such that structure (22) is immersed in liquid (50) (i.e. FIG. 1 rotated 90 degrees); and also such that outlet (25) is clearly observable;
  [Xb.] observing bottle (40) to confirm structure (22) is immersed in liquid (50);
  [Xc.] slowly collapsing bottle (40) at points S and point T with the thumb and forefinger approximately 0.5 cm such that liquid (50) is visible at outlet (25); and the end of liquid (50) is located at or near the outlet (25) as shown in FIG. 5 (i.e. 0.05 cm is near the outlet; and 0.07 cm beyond the outlet is near the outlet); an objective of this step includes to confirm that tip (100A) contains liquid (50);
  [Xd.] slowly removing the collapsing force at points S and point T; and simultaneously maintain enough compressive force to hold the bottle; and simultaneously rotating bottle (40) to a dispensing position shown in FIG. 6 and FIG. 1 such that gas (60) surrounds structure (22); it requires about 1 to 2 seconds to remove the collapsing force; and do not remove the collapsing force rapidly (i.e. within 30 ms is rapidly);
  [Xe.] waiting approximately 1 to 2 seconds; and do not wait more than approximately 5 seconds to execute step [Xf.];
  [Xf.] collapsing bottle (40) at points S and point T with the thumb and forefinger at approximately 0.5 cm per second, or approximately 0.4 cm per second (i.e. 0.5 cm/1 second, or 0.4 cm/1 second); and dispensing a pbod on the test paper;
  NOTE: outlet (25) is disposed approximately 9 cm above the test paper for all trials in Experiment X;
  [Xg.] placing bottle (40) at a typical rest position for the VISINE bottle (i.e. the axis of tube (27) is horizontal); and measuring the outer diameter of the liquid on the test paper; and recording data. End of EXPERIMENT X.
  EXPERIMENT V is executed according to the following steps [Va.] to [Vc.] as follows:
  [Va.] Holding bottle (40) at points S and point T, and rotating bottle (40) such that structure (22) is immersed in liquid (50) (i.e. FIG. 1 rotated 90 degrees);
  [Vb.] rotating bottle (40) to an inverted position of FIG. 1 (i.e. the initial velocity of the pbod is in the opposite direction of a gravity vector);
  [Vc.] collapsing bottle (40) at points S and point T with the thumb and forefinger at approximately 0.5 cm per second, or approximately 0.4 cm per second; and observing results; and recording results. End of EXPERIMENT V.
  EXPERIMENT H is executed according to the following steps [Ha.] to [Hc.] as follows:
  [Ha.] Holding bottle (40) at points S and point T, and rotating bottle (40) such that structure (22) is immersed in liquid (50) (i.e. FIG. 1 rotated 90 degrees);
  [Hb.] rotating bottle (40) such that the axis of tube (27) is horizontal and structure (22) is surrounded by gas (60);
  [Hc.] collapsing bottle (40) at points S and point T with the thumb and forefinger at approximately 0.5 cm per second, or approximately 0.4 cm per second; and observing results; and recording data. End of EXPERIMENT H.
  EXPERIMENT L is executed according to the following steps [La.] to [Lc.] as follows:
  [La.] Holding bottle (40) at points S and point T such that the axis of tube (27) is vertical and liquid (50) is disposed at the lower portion of bottle (40) as shown in FIG. 1; and subsequently rotating bottle (40) such that structure (22) is immersed in liquid (50) (i.e. FIG. 1 rotated 90 degrees);
  [Lb.] rotating bottle (40) to 45 degrees from the position of FIG. 1 (i.e. the initial velocity of the pbod is 45 degrees from a gravity vector);
  [Lc.] collapsing bottle (40) at points S and point T with the thumb and forefinger at approximately 0.5 cm per second, or approximately 0.4 cm per second; and observing results; and recording data. End of EXPERIMENT L.
  EXPERIMENT U is executed according to the following steps [Ua.] to [Ud.] as follows:
  [Ua.] Notifying another person the following steps are an experiment;
  [Ub.] the present Inventor giving verbal and visual instructions to this other person; where these instructions are to execute Experiment X according to the steps [Xa.] to [Xg.] set forth herein;
  [Uc.] Inventor observing this other person execute steps [Xa.] to step [Xg.];
  [Ud.] Inventor observing, recording, and measuring the results of the trial. End of EXPERIMENT U.
  EXPERIMENT E is executed according to the following steps [Ea.] to [Ef.] as follows:
  [Ea.] Removing tip (201) from bottle (200) (do not remove tube (202) from tip (201));
  [Eb.] injecting approximately 20 to 60 ul of liquid (207) in dispensing tip (201) such that the upper surface (211) is approximately 0.2 cm above opening (35);
  [Ec.] replacing tip (201) on bottle (200);
  [Ed.] rotating bottle (200) such that the axis of tube (202) is generally vertical as shown in FIG. 8;
  [Ee.] collapsing bottle (200) at points S and point T at an approximate constant speed of 0.1 cm per second, or 0.4 cm per second (collapse with thumb and forefinger);
  [Ef.] observing the upper end of tube (202). End of EXPERIMENT E.
  EXPERIMENT Q is executed according to the following steps [Qa.] to [Qe.] as follows:
  [Qa.] Removing tube (302) from tube (301);
  [Qb.] injecting 6.7 ul of liquid into the lower end (310) of tube (301) using metered syringe (1 cc/29 guage needle);
  [Qc.] replacing tube (302) into tube (301); and tube (302) extends approximately 0.5 cm into tube (301); and maintain an appropriate compressive force at points S and point T such that the dose of liquid remains in a static state (no motion); and the dose of liquid is located at the lower end of tube (301);
  [Qd.] rotating bottle (300) such that the axis of tube (302) is generally vertical as shown in FIG. 9;
  [Qe.] collapsing bottle (300) at points S and point T with the thumb and forefinger at approximate constant speed of approximately 0.1 cm per second to approximately 0.3 cm per second, and a total distance of approximately 0.5 cm; and observing the discrete pbod (i.e. pbod (70) in FIG. 9).
  NOTE: The residual liquid in tube (302) is not removed; and the residual liquid in tube (301) is not removed. Tube (301) and tube (302) contain residual liquid at the end of step [Qe.].
  NOTE: An additional step [Qf.] is added for trials Nos. 12 to 39. This step [Qf.] is as follows:
  [Qf.] removing tube (302) from tube (301); and placing tube (302) on a horizontal surface; and measuring the location and width of the residual liquid in tube (302).
  End of EXPERIMENT Q.
  EXPERIMENT M is executed according to the following steps [Ma.] to [Mc.] as follows:
  [Ma.] Placing one sheet of test paper on scale;
  [Mb.] closing all sides of breeze break; and set zero function;
  [Mc.] dispensing pbod onto test paper according to steps in Experiment X; and recording electronic display of the mass.
• End of EXPERIMENT M.

  TABLE X
  R29 L Experiment X prototype R29
  Liquid (50) = REFRESH LIQUIGEL (lot No. 30469)
  (ALLERGAN, INC.) (expire: Mar 06)

  	TRIAL	O	D (in)

  19 July 2004 (19.07.04)

  		1		0.170-7:07 am
  		2		0.180 air
  		3		0.170 27.5 C.
  		4		0.170
  		5		0.170
  		6		0.170
  		7		0.160
  		8		0.170-7:13 am
  		9	1x	0.170
  		10		0.170
  		11		0.150
  		12		0.170
  		13		0.170
  		14		0.160
  		15		0.180
  		16		0.170-7:19 am
  		17		0.180
  		18		0.180
  		19		0.180
  		20		0.180
  		21		0.180
  		22		0.190
  		23		0.170
  		24		0.170
  		25		0.160
  		26		0.180
  		27		0.170
  		28		0.160
  		29		0.160
  		30		0.180
  		31		0.170
  		32		0.170
  		33		0.170
  		34		0.160
  		35		0.170
  		36		0.180
  		37		0.160
  		38		0.160
  		39		0.160
  		40		0.170
  		41		0.180
  		42		0.160
  		43		0.160
  		44		0.160
  		45		0.170
  		46		0.150
  		47		0.180
  		48		0.170
  		49		0.150
  		50		0.170
  		51		0.180
  		52	1x	0.150
  		53		0.150
  		54		0.180
  		55		0.170
  		56		0.170
  		57		0.180
  		58		0.170
  		59		0.150
  		60		0.180
  		61		0.160
  		62		0.160
  		63		0.160
  		64		0.170
  		65		0.170
  		66		0.170
  		67		0.170
  		68	1x	0.160
  		69		0.170
  		70		0.160
  		71		0.160-7:59 am
  		72		0.180
  		73		0.170
  		74		0.170
  		75		0.170
  		76		0.150
  		77		0.170
  		78		0.170-8:05 am
  		79		0.170
  		80	2x	0.180
  		81		0.180
  		82		0.150
  		83		0.150
  		84		0.160
  		85		0.160
  	8:11 am-	86		0.180
  		87		0.180
  		88		0.170
  		89		0.180
  		90		0.170
  		91		0.160
  		92		0.180
  		93		0.170
  		94		0.170
  		95		0.160
  		96		0.150
  		97		0.170
  	air	98		0.170
  	28.0 C.	99		0.170
  	8:22 am-	100		0.180
  	19 July	101		0.190
  	2004	102		0.180
  		103		0.180
  		104		0.180
  		105		0.170
  		106		0.180
  		107		0.180
  		108	1x	0.170
  		109		0.180
  		110		0.180
  		111		0.180
  		112		0.170
  		113		0.180
  		114		0.170
  		115		0.180
  		116		0.170
  		117		0.170
  		118		0.180
  		119	2x	0.180
  		120		0.170

  NOTE: Approximately 5 trials per 100 trials do not appear to

  have any bubbles; the bubbles may be small and not observable, or

  the bubbles burst prior to observing on test paper. All pbods in

  these trials for this Experiment X contain approximately 3 to 5

  bubbles having a diameter of approximately 0.02 cm diameter,

  except as noted above.

  		121		0.170
  		122		0.170
  		123		0.170
  		124		0.170
  		125		0.170
  		126		0.160
  		127		0.160
  		128		0.150
  		129		0.170
  		130		0.180-5:10 pm
  		131		0.170 air
  		132		0.160 29.0 C.
  		133		0.160
  		134		0.170
  		135		0.180
  		136		0.180
  		137		0.180
  		138		0.170
  		139		0.180
  		140		0.170
  		141		0.180
  		142	1x	0.160
  		143		0.190
  		144		0.180
  		145	1x	0.180
  		146	1x	0.180
  		147		0.180
  		148		0.180
  		149		0.180
  		150		0.180-5:24 pm
  		151		0.170
  		152		0.170
  		153		0.190
  		154		0.160
  		155		0.170
  		156		0.170
  		157		0.170
  		158		0.180
  		159		0.180
  		160		0.170-5:32 pm
  		161		0.180
  		162		0.170
  		163		0.190
  		164		0.170
  		165		0.160
  		166		0.160
  		167		0.180
  		168		0.170
  		169		0.170
  		170		0.180-5:39 pm
  		171		0.190
  		172		0.160
  		173		0.180
  		174		0.160
  		175		0.150
  		176		0.180
  		177		0.180
  		178		0.180
  		179		0.180
  		180		0.180
  		181		0.170
  		182		0.160
  		183		0.170
  		184		0.170
  		185		0.170
  		186		0.170
  		187		0.160
  		188		0.170
  		189		0.170
  		190		0.170
  		191		0.180
  		192		0.180
  		193		0.160
  		194		0.160
  		195		0.160
  		196		0.160
  		197		0.160
  		198		0.140
  		199		0.160
  		200		0.170-6:02 pm
  	11:00 pm-	201		0.170
  		202		0.180
  	11:02 pm-	203		0.170
  	6:51 am-	204		0.180
  	21 July	205		0.170
  	2004	206		0.170
  		207		0.180
  		208		0.170
  		209		0.180
  		210		0.180
  		211		0.180
  		212		0.180
  		213		0.180
  		214		0.180
  		215	1x	0.150
  		216		0.180
  		217		0.170
  		218		0.180
  		219		0.190
  		220		0.180
  		221		0.180
  		222		0.180
  		223		0.180
  		224		0.180
  		225		0.180
  		226		0.180
  		227		0.180
  		228		0.180
  		229		0.180
  	7:10 am-	230		0.180
  	7:20 am-	231		0.190
  	air	232		0.170
  	27.5 C.	233		0.170
  		234		0.160
  		235		0.170
  		236		0.180
  		237		0.170
  		238		0.170
  		239		0.180
  		240		0.180

  NOTE: prototype R29 is not used between 21 July 2004, 10:30 pm

  to 24 July 2004, 8:40 am; and cap (45) and seal (44) is on neck (43)

  during this period of rest; TOTAL hours at rest between trial 600

  to trial 601: 58 hours.

  21 July 2004 (21.07.04)

  		241		0.180
  		242		0.180-7:28 am
  		243		0.160
  		244		0.170
  		245		0.180
  		246		0.180
  		247		0.180
  		248		0.180
  		249		0.160
  		250		0.160-7:33 am
  		251		0.170-9:28 am
  		252		0.180 air
  		253	1x	0.170 27.8 C.
  		254		0.150
  		255		0.180
  		256		0.170
  		257		0.170
  		258		0.180
  		259		0.170
  		260		0.170
  		261		0.170
  		262		0.170-9:36 am
  		263		0.190-9:39 am
  		264	1x	0.180
  		265		0.160
  		266		0.190
  		267		0.180
  		268		0.170
  		269		0.180
  		270		0.170
  		271		0.180-9:46 am
  		272		0.180-9:49 am
  		273		0.180
  		274		0.170
  		275		0.180
  		276		0.180
  		277		0.150
  		278		0.180
  		279		0.180
  		280		0.180
  		281		0.180
  		282		0.180
  		283		0.170-9:56 am
  		284		0.180
  		285		0.160
  		286		0.170
  		287		0.170
  		288	2x	0.170
  		289	2x	0.160
  		290		0.180-10:02 am
  		291		0.190
  		292		0.180
  		293		0.180
  		294		0.180
  		295		0.180
  		296		0.180
  		297		0.170
  		298	1x	0.170
  		299		0.190
  		300		0.180-10:10 am
  		301		0.190-4:35 pm
  		302		0.180
  		303		0.180
  		304		0.190
  		305		0.160
  		306		0.180
  		307		0.180
  		308		0.170
  		309		0.170
  		310		0.170
  		311		0.180
  		312		0.170
  		313		0.170
  		314		0.180
  		315		0.170
  		316	1x	0.160
  		317		0.180
  		318		0.180
  		319		0.160
  	4:49 pm-	320		0.180
  		321		0.180
  		322		0.180
  		323		0.180
  		324		0.160
  		325		0.170
  		326		0.160
  		327		0.160
  		328		0.180
  		329		0.170
  		330		0.180
  		331	1x	0.180
  		332		0.180
  	4:58 pm-	333		0.180
  		334		0.180
  		335		0.170
  		336		0.180
  		337		0.150
  		338		0.180
  		339		0.160
  		340	1x	0.160
  		341		0.150
  		342		0.180
  		343		0.170
  		344		0.170
  		345	1x	0.170
  		346		0.180
  		347		0.180
  		348		0.170
  		349		0.180
  	5:11 pm-	350	1x	0.180
  		351		0.180
  		352		0.170
  		353		0.150
  		354		0.160
  		355		0.180
  		356		0.180
  	21 July	357		0.160
  	air	358		0.190
  	30.0 C.	359		0.160
  	5:17 pm-	360		0.160

  NOTE: prototype R29 is not used between 24 July 2004, 8:40 am to

  24 July 2004, 10:22 pm; and cap (45) and seal (44) is on neck (43)

  during this period of rest; TOTAL hours at rest between trial 601

  to trial 602: 14 hours. Further, prototype R29 is allowed to rest

  for periods of between 5 to 10 hours, without cap (45); and

  dispenses a pbod on the first subsequent trial.

  		361		0.180-5:33 pm
  		362		0.180 air
  		363		0.190 27.7 C.
  		364		0.180
  		365		0.160
  		366		0.180
  		367	1x	0.160
  		368		0.180
  		369		0.190
  		370		0.190
  		371		0.180
  		372		0.190
  		373		0.170
  		374		0.150
  		375		0.170
  		376		0.170
  		377	2x	0.180
  		378		0.170 air
  		379		0.180 28.0 C.
  		380		0.180-5:46 pm
  		381	1x	0.200
  		382		0.180
  		383		0.180
  		384		0.180
  		385		0.180
  		386		0.180
  		387		0.180
  		388		0.180
  		389	1x	0.190
  		390		0.190-5:52 pm
  		391		0.160
  		392		0.180
  		393		0.160
  		394		0.190
  		395		0.160
  		396		0.170
  		397		0.180
  		398		0.180 air
  		399		0.170 29.1 C.
  		400		0.180-5:58 pm
  		401		0.180-6:37 pm
  		402		0.180
  		403		0.190
  		404		0.180
  		405		0.180
  		406		0.180
  		407		0.180
  		408		0.170
  		409		0.190
  		410		0.170
  		411		0.190
  		412		0.180
  		413		0.180
  		414		0.160
  		415	1x	0.170
  		416		0.180
  		417		0.170
  		418	2x	0.160
  		419		0.180
  		420		0.180-6:49 pm
  		421		0.190 air
  		422		0.170 27.5 C.
  		423		0.170
  		424		0.170
  		425		0.160
  		426		0.170
  		427		0.170
  		428		0.160
  		429		0.140
  		430		0.170-6:57 pm
  		431		0.180-6:59 pm
  		432		0.180
  		433		0.170
  		434		0.150
  		435		0.150
  		436		0.160
  		437		0.170
  		438	1x	0.140
  		439	1x	0.170
  		440		0.170
  		441		0.160
  		442		0.150
  		443		0.170
  		444		0.160
  		445		0.170
  		446		0.150
  		447		0.180
  		448		0.170
  		449		0.170
  		450		0.150-7:11 pm
  		451		0.160
  		452		0.160
  		453		0.160
  		454		0.180
  		455		0.170
  		456		0.160
  		457		0.180
  		458		0.170
  		459		0.160
  	7:19 pm-	460		0.160
  		461		0.180
  		462		0.170
  		463		0.150
  		464		0.160
  		465		0.160
  		466		0.160
  		467		0.180
  		468		0.160
  		469		0.160
  		470-7:25		0.160
  		471 pm		0.160
  		472		0.160
  		473		0.150
  		474	1x	0.170
  		475		0.160
  		476		0.170
  		477		0.160
  		478		0.150
  		479	1x	0.170
  		480		0.170
  		481		0.160
  		482		0.150
  		483		0.150
  		484		0.150
  	7:34 pm-	485		0.160
  		486		0.150
  		487		0.150
  		488		0.160
  		489		0.180
  		490	1x	0.160
  		491		0.160
  		492		0.150
  		493		0.160
  		494		0.160
  		495		0.160
  		496		0.160
  		497		0.150
  		498		0.170
  		499		0.140
  	7:45 pm-	500		0.170
  	9:11 pm-	501		0.160
  	air	502		0.160
  	28.5 C.	503		0.150
  		504		0.150
  		505		0.150
  		506		0.170
  		507		0.160
  		508		0.170
  		509		0.150
  		510		0.150
  		511	1x	0.150
  		512		0.160
  		513		0.150
  		514		0.150
  		515		0.170
  		516	1x	0.130
  		517	1x	0.160
  		518	2x	0.150
  		519		0.140
  		520		0.140-air
  		521		0.170 28.8 C.
  		522		0.160
  		523		0.150
  		524		0.170
  		525		0.140
  		526		0.170
  		527	1x	0.170
  		528		0.180
  		529		0.170
  		530		0.170
  		531		0.160-9:31 pm
  		532		0.180
  		533	1x	0.160
  		534		0.160
  		535		0.160
  		536		0.170
  		537		0.170
  		538	1x	0.150
  		539	2x	0.170
  		540		0.160
  		541		0.180
  		542	1x	0.120
  		543	1x	0.170
  		544		0.160
  		545		0.160
  		546		0.150
  		547		0.170
  		548		0.160
  		549		0.160
  	9:43 pm-	550		0.170
  		551		0.160
  		552		0.170
  		553		0.160
  		554		0.160
  		555		0.170
  		556		0.160
  		557		0.170
  		558		0.150
  		559		0.160
  		560-9:50		0.170
  		561 pm		0.160
  		562		0.150
  		563		0.170
  		564	1x	0.160
  		565		0.160
  		566		0.170
  		567		0.170
  		568		0.170
  		569		0.160
  	9:58 pm-	570		0.160
  		571		0.170
  		572		0.160
  		573		0.140
  		574		0.150
  	10:03 pm-	575		0.160
  		576		0.160
  		577		0.170
  		578		0.180
  		579		0.150
  		580		0.160
  	10:18 pm-	581		0.180
  		582		0.180
  		583		0.160
  		584		0.170
  		585		0.180
  		586		0.160
  		587		0.190
  		588		0.160
  		589		0.180
  	10:23 pm-	590		0.180
  	10:25 pm-	591		0.190
  		592		0.170
  		593		0.160
  		594		0.180
  		595	1x	0.150
  		596	1x	0.160
  	air	597		0.160
  	28.0 C.	598	1x	0.170
  	21 July	599		0.170
  	10:30 pm-	600	1x	0.170
  	8:40 am-	601		0.180
  	24 July
  	10:22 pm-	602		0.180
  	24 July	603		0.170
  	air	604		0.150
  	29.0 C.	605		0.160
  		606		0.160
  		607		0.150
  		608		0.160
  	10:27 pm-	609		0.170
  	10:29 pm-	610		0.170
  	11:26 pm-	611		0.160
  	air	612	1x	0.170
  	28.7 C.	613		0.170
  		614		0.150
  		615		0.130
  		616		0.160
  		617	1x	0.160
  		618		0.170
  		619		0.160
  	11:33 pm-	620		0.160
  	24 July

  NOTE: explanation of table data: The entry indicated below means:

  the air temperature is 28.0 C. at 10:30 pm on 21 July 2004;

  and trial No. 600 is executed at 10:30 pm on 21 July 2004; and

  the diameter of liquid on test paper is 0.170

  inches; and there is one overspray drop

  (or hollow body), which is 0.008 inches diameter.

  air

  28.0 C.

  21 July

  10:30 pm-600 1x 0.170

  R29 L Experiment X prototype R29

  Liquid (50) = REFRESH LIQUIGEL (lot No. 30469)

  Trials Nos. 621 to 670 dispense pbods having a dia. Between 0.150 to

  0.180; and four occurrence of overspray.

  	Trial	O	D
  	671		0.200-11:33 am
  	672		0.180 air
  	673		0.180 27.0 C.
  	674		0.170
  	675		0.180
  	676		0.160
  	677		0.180
  	678		0.150
  	679		0.170
  	680		0.160-11:38 am 15 Aug 2004

  SUMMARY OF TABLE X R29 L DATA

  D = measured diameter of liquid on test paper, in inches;

  O = overspray; 1x = one drop; 2x = 2 drops, etc.;

  no entry = no overspray

  TOTAL TRIALS: 620

  TOTAL CONSECUTIVE SUCCESSFUL TRIALS: 620

  maximum dia./v = 0.200/8 ul

  minimum dia./v = 0.120/4.5 ul

  standard deviation (volume): 0.5

  average diameter

  on test paper: 0.169

  average volume: 6.5 ul

  volume/quantity of occurrence

  8.0 ul =	1
  7.5 ul =	27
  7.0 ul =	196
  6.5 ul =	191
  6.0 ul =	140
  5.6 ul =	54
  5.3 ul =	8
  5.0 ul =	2
  4.5 ul =	1
  Total trials =	620

  total trials with overspray: 48

  NOTE: these volumetric quantities

  are estimates based on

  experimental data.

  NOTE: CONSECUTIVE meaning: there are no attempts to dispense a

  pbod during the above-noted periods of rest between trials.

  IMPORTANT NOTE: ten occurrence of overspray is observed to be a

  hollow body (i.e. one ball of liquid encloses one ball of air).

  All occurrence of overspray is measured to be approximately 0.008

  inches diameter. In light of the results of Experiment Q, it is

  contemplated that a possible source of the overspray is residual liquid

  is ejected immediately after the pbod is ejected.

• AVERAGE TIME DISTRIBUTION IN EXPERIMENT X
  The following indicates the approximate average time Inventor
  utilized to execute the respective steps of Experiment X:

  Begin, pick up bottle; and rotate bottle such	4	s
  that outlet (25) is observable:
  Begin, to collapse bottle;	7 to 10	s
  and liquid reaches near outlet (25):
  begin, release collapsing force;	4 to 5	s
  and axis of tube (27) is vertical:
  begin, place bottle at rest position;	10 to 12	s
  and pick up scale and magnifying glass;
  and measure diameter of liquid:
  begin place scale and magnifying glass on table;	10 to 12	s
  writing results in laboratory notebook with ink
  pen; writing trial No. on test paper and notebook:
  AVERAGE TOTAL TIME PER TRIAL:	45	seconds

• TABLE U R29 L
  Experiment U
  20 Jul. 2004 (20.07.04) Liquid (50):
  REFRESH LIQUIGEL prototype R29

  Person No. 1:	age at time of trial:	74 years
  	general health:	4
  	eye glasses:	yes bi-focal
  RESULTS person No. 1:	trial No. 1:	successfully dispensed pbod having 0.180 in.
  		dia. on test paper. This person requires relatively
  		more detailed instructions. i.e. this person has
  		difficulty understanding instructions. This person
  		made the following comment: I believe I am capable
  		to utilize prototype R29 to instill a pbod on my eye.
  Person No. 2:	age at time of trial:	11 years
  	general health:	10
  	eye glasses: no
  RESULTS person No. 2:	trial No. 1:	0.170 in.
  	trial No. 2:	0.180 in.
  	trial No. 3:	0.180 in.
  person No. 3:	age at time of trial:	60 years
  	general health:	8
  	eye glasses:	yes tri-focals
  RESULTS person No. 3:	trial No.
  	1 0.190
  	2 0.100
  	3 0.200
  	4 0.200
  	5 0.210
  	6 0.200
  	7 0.200
  	8 0.200
  	9 0.200
  	10 0.200
  	11 0.230

• TABLE Q R11 L
  13 FEB. 2004 (Feb. 02, 2004)
  EXPERIMENT Q PROTOTYPE R11
  Liquid (50) = REFRESH LIQUIGEL (ALLERGAN) = 7 ul
  UPC: 300239205307
  Trial Nos. 1 to 10 successfully dispense a pbod, each having an
  estimated diameter of 3.0 mm; and no overspray occurs.

  Trial No.	D (mm)	Trial No.	D (mm)	Trial No.	D (mm)

  40	3.0-air	96	3.0	152	3.0
  41	3.0 26.7° C.	97	3.0	153	3.0
  42	3.0	98	3.0	154	3.0
  43	3.0-9:30 pm	99	3.0	155	3.0
  44	3.0 13 FEB	6:06 pm-100	3.0	156	3.0
  45	3.0 2004	101	3.0-9:54 am	157	3.0
  46	3.0	102	3.0 16 FEB	158	3.0
  47	3.0	103	3.0 2004	159	3.0
  48	3.0	104	3.0	160	3.0
  49	3.0	105	3.0	161	3.0
  50	3.0	106	3.0	162	3.0
  51	3.0	107	3.0	163	3.0
  52	3.0-11:44 am	108	3.0	164	3.0
  53	3.0 14 FEB	109	3.0	165	3.0
  54	3.0 2004	110	3.0	166	3.0
  55	3.0	111	3.0	167	3.0
  56	3.0	112	3.0	168	3.0
  57	3.0	113	3.0	169	3.0
  58	3.0	114	3.0	11:05 am-170	3.0
  59	3.0	115	3.0	171	3.0
  60	3.0	116	3.0	172	3.0
  61	3.0	117	3.0	173	3.0
  62	3.0	118	3.0	174	3.0
  63	3.0	119	3.0	175	3.0
  64	3.0	120	3.0	176	3.0
  65	3.0	121	3.0	177	3.0
  66	3.0-12:13 pm	122	3.0	178	3.0
  67	3.0	123	3.0	179	3.0
  68	3.0	124	3.0	180	3.0
  69	3.0	125	3.0	181	3.0
  70	3.0	126	3.0	182	3.0
  71	3.0	127	3.0	183	3.0
  72	3.0	128	3.0	184	3.0
  73	3.0	129	3.0	185	3.0
  74	3.0	130	3.0	186	3.0
  75	3.0	131	3.0	187	3.0
  76	3.0 air	132	3.0	188	3.0
  77	3.0 24.5° C.	10:16 am-133	3.0	189	3.0
  78	3.0 15 FEB	134	3.0	190	3.0
  79	3.0 2004	135	3.0	191	3.0
  80	3.0-5:37 pm	136	3.0	192	3.0
  81	3.0	137	3.0	193	3.0
  82	3.0	138	3.0	194	3.0
  83	3.0	139	3.0	195	3.0
  84	3.0	140	3.0	196	3.0
  85	3.0	141	3.0	197	3.0
  86	3.0	142	3.0	198	3.0
  87	3.0	143	3.0	199	3.0
  88	3.0	144	3.0	200	3.0
  89	3.0	145	3.0	201	3.0
  90	3.0	146	3.0	203	3.0
  91	3.0	147	3.0	11:26 am-204	3.0
  92	3.0	148	3.0
  93	3.0	149	3.0
  94	3.0	150	3.0
  95	3.0	151	3.0
  EXPLANATION OF TABLE Q R11 L DATA
  Quantity of liquid (50) injected into tube (301) is 7 ul;
  D = estimated diameter of discrete pbod in millimeters (mm);
  v = volume of residue in tube (302) in microliters.
  NOTE:
  overspray does NOT occur for any trials in Experiment Q, therefore, this item is omitted in the following tables.
  NOTE:
  trials Nos. 12 to 39 indicate the location and length of the residual liquid in tube (302). Dash (-) = air; “x” = liquid. The table contains a series of dashes (-) and “x” There is a total of thirty characters for each line (i.e. trial No. 13 contains 28 dashes and 2 “x”). Each character represents 1 mm length of tube (302). Tube (302) is 30 mm length, therefore 30 characters per line. Therefore, each character represents the
  # respective location (i.e. in trial 13, the residual liquid in tube (302) is 2 mm length; and located at the upper end of tube (302); and air occupies the lower 28 mm length ). “v” equals the calculated volume of the residual liquid (tube 302). In trial No. 22, “l” equals 0.5 mm length.

• TABLE U R29 L
  Experiment U
  15 Aug. 2004 (15.08.04) Prototype R29
  Liquid (50) = REFRESH LIQUIGEL
  (lot No. 30469) (ALLERGAN, INC.)

  		trial
  Person No. 1:		No.	results
  same person		1	steps executed incorrectly/no liquid
  of 20 Jul.			ejected
  2004		2	pbod/0.170 in. dia./no overspray
  		3	steps executed incorrectly/pendant drop
  		4	steps executed incorrectly/no liquid
  			ejected
  	11:04-	5	steps executed incorrectly/pendant drop
  	am	6	pbod/0.180 in. dia./no overspray
  NOTE:
  this is the same person No. 1 (age 74), which executed Experiment U on 20 Jul. 2004; the general health of this person is now rated at 3; on 15 August, this person has a broken left wrist, which was broken about 30 Jul. 2004; wearing a cast; having moderate continuous pain; using EXTRA STRENGTH TYLENOL for pain; reluctant to execute experiment; required complete instructions of the experimental steps; is unable to remember the appropriate experimental
  # steps; used right hand to execute experiment.

• TABLE X R29 L
  Experiment X
  Liquid (50) = REFRESH LIQUIGEL (lot No. 30469) prototype R29
  Trials Nos. 621 to 670 dispense pbods having a dia. Between 0.150 to
  0.180; and four occurrence of overspray.

  	Trial	0	D

  	671	0.200-11:33 am
  	672	0.180 air
  	673	0.180 27.0 C
  	674	0.170
  	675	0.180
  	676	0.160
  	677	0.180
  	678	0.150
  	679	0.170
  	680	0.160-11:38 am 15 Aug. 2004

• The above tables of empirical data are labeled according to the experiment, the prototype utilized in the experiment, and the liquid (50) utilized in the experiment. For example, TABLE X R29 L is Experiment X, prototype R29, and liquid (50) is REFRESH LIQUIGEL.
• Gas (60) is air for all trials in all experiments. The present Inventor executes all trials in all experiments, except as noted in Experiment U.
• EXPERIMENT V RESULTS: prototype R29; liquid (50)=REFRESH LIQUIGEL; vertical orientation (opposite direction of a gravity vector): Trial No. 1 dispenses a pbod having a narrow parabolic path, where the height is about 5 cm, and the horizontal distance is about 1 cm. Trials No. 2 to 5 are not successful. Trials Nos. 6 and 7 dispense a pbod (similar path to trial No. 1). Trial Nos. 8 to 10 are not successful. Trial No. 11 dispenses a pbod (similar path to trial No. 1); and each pbod contains approximately 3 ul of liquid (50). Dose (77) is about 3 ul; and dose (10) is about 0.7 ul; and each pbod contains approximately three bubbles (75).
• EXPERIMENT H RESULTS: prototype R29; liquid (50)=REFRESH LIQUIGEL: horizontal orientation: Trial No. 1 dispenses a pbod a horizontal distance of about 7 cm; Trials Nos. 2 to 4 are not successful. Trials Nos. 5 and 6 dispense a pbod a horizontal distance of about 4 cm. Trials Nos. 7 to 10 are not successful. And each pbod contains approximately 3 ul of liquid (50). Dose (77) is about 3 ul; and dose (10) is about 0.7 ul; and each pbod contains approximately three bubbles (75).
• EXPERIMENT L RESULTS: prototype R29; liquid (50)=REFRESH LIQUIGEL: 45 degree orientation: Trial No. 1 is not successful. Trial No. 2 and 3 dispenses a pbod having a parabolic path. Trial Nos. 4 to 7 are not successful. Trial Nos. 8 and 9 dispense a pbod having a parabolic path; and each pbod contains approximately 3 ul of liquid (50). Dose (77) is about 3 ul; and dose (10) is about 0.7 ul; and each pbod contains approximately three bubbles (75).
• The following is a summary of the events, which occur in Experiment X. Including, first the bottle (40) is in a position similar as shown in FIG. 1, and dispensing tip (100A) does not have cap (45); and cap (42) and seal (41) form a leak-tight seal; second, bottle (40) is rotated to a position shown in FIG. 5 such that structure (22) is immersed in liquid (50); and third, liquid (50) flows from left to right in FIG. 5; and fourth, liquid (50) stops flowing upon reaching outlet (25) as shown in FIG. 5 (i.e. FIG. 5 depicts both a dynamic state and a static state); fifth, liquid (50) flows from right to left in FIG. 5; and sixth, liquid (50) stops flowing upon reaching opening (35) as shown in FIG. 6 (i.e. the lower end of dose (77) is at opening (35) in FIG. 6), and the upper portion of tip (100A) contains a dose (77) of liquid (50), and a portion of this dose (77) is disposed between structure (22); seventh, a motive gas (65) imposes this dose (77) to flow from top to bottom in FIG. 7 as shown by the vertical arrow; eighth, motive gas (65) forms a dose (10) of gas (60), and dose (77) encloses this dose (10), and dose (10) has the form of a plurality of bubbles (75), and this dose (10) is the complete dose of gas in pbod (70). FIG. 7 does not show the inherent phenomenon, which causes dose (10) to be formed.
• The following is a summary of the events, which occur in Experiment V. Including, first, structure (22) is surrounded by air; and second, structure (22) is immersed in liquid (50) for a period of approximately 2 to 3 seconds; and third, a dose of liquid (50) inherently flows between the two flat walls of structure (22) (i.e. capilary); and fourth, the bottle is rotated such that structure (22) is surrounded by gas (60); and fifth, a motive gas (65) forms a dose (10)of gas (60), and this dose (10) has the form of a plurality of bubbles (75), and this dose (10) is the complete dose of gas in one pbod (70).
• The events in Experiment H, and Experiment L are similar to the above-described events of Experiment V.
• EXPERIMENT E RESULTS: prototype R22; liquid (207) is REFRESH LIQUIGEL (ALLERGAN, INC.): Experiment E forms a succession of identical bubbles (204). For a collapsing speed of about 0.1 cm per second, the diameter of the bubbles is approximately 0.03 cm, and spaced about 0.09 cm equally distant; and this trial contains about 30 bubbles. Several additional consecutive trials are executed having identical results to the above-described results of Experiment E.
• (Experiment E results) For a collapsing speed of about 0.4 cm per second, the bubbles are about 0.007 cm diameter, and spaced about 0.04 cm equally distant, and this trial contains about 70 bubbles (seventy). Several additional consecutive trials are executed having identical results to the above-describes results.
• To summarize the events in Experiment E, including, first, bottle (200) contains air (212); and second, about sixty microliters of liquid (207) is disposed in tip (201) such that the upper surface (211) is about 0.2 cm above opening (35); and third, tip (201) is place on bottle (200); and fourth, a pressure drop over opening (35) imposes liquid (207) to flow down into tube (202); and fifth, upon near depletion of liquid in tip (201), a succession of identical bubbles (204) is formed in the upper portion of tube (202); liquid (207) encloses bubbles (204).
• EXPERIMENT E RESULTS: Variations of prototype R22 have disensed pbods. For example, where the length of tube (202) is 1 cm or 0.5 cm; and the pbod contains about 7 ul liquid (207).
Manufactures
• A & D ENGINEERING, Milpitas, Calif. 95035, U.S.
• ALLERGAN, INC., Irvine, Calif. 92612, U.S.
• BECTON DICKINSON, Franklin Lakes, N.J. 07417, U.S.
• BOTTLING GROUP, LLC, Riverside, Calif. 92606, U.S.
• JB WELD COMPANY, Sulphur Springs, Tex. 75483, U.S.
• L.S. STARRETT, Athol, Mass., U.S.
• PFIZER INC CONSUMER HEALTHCARE, Morris Plains, N.J., 07950, U.S.
• SPECTRUM CHROMOTOGRAPHY, Houston, Tex. 77073, U.S.
• SPERLE SCALES, INC, Santa Fe Springs, Calif. 90670 U.S.
• STANLEY TOOLS, New Britain, Conn. 06053, U.S.
BEST MODE FOR CARRYING OUT THE INVENTION
• The present disclosure includes several pioneering discoveries. Including, a complete dose of gas formed essentially by a motive gas; and a pbod formed utilizing inherent residual liquid in a discharge tube; and a pbod ejected from any indiscriminate selected initial velocity; and a succession of identical bubbles capable of forming the complete dose of gas in one pbod.
• The best mode for carrying out these present discoveries is set forth in the present respective experiments and prototypes. The best mode to form a complete dose of gas is imposing an appropriate motive gas to flow through an appropriate flow channel. Where this motive gas imposes a dose of liquid to flow through the flow channel; and the motive gas forms the complete dose of gas.
Alternate Embodiments
• There are many variations of dispensing tip (100A), which are capable of dispensing a pbod. Several of these embodiments are set forth in Coffelt, Jr. U.S. patent application Ser. No. 10/827,901 filed 19 Apr. 2004 (19.04.04). For example, structure (22) may have an arch shape. The prototypes in Ser. No. 10/827,901 dispense pbods, and it is contemplated that these alternate embodiments will have successful results in conjuntction with Experiment X. Experiment X and the prototypes of Ser. No. 10/827,901 should have similar results to the above results. The prototypes in Ser. No. 10/827,901 have dispensed 3 ul pbods having initial velocities of 135 degrees, 45 degrees, including other orientations.
• There are clearly many well known methods to verify the location of dose (77) in FIG. 6. And also, many well known methods to verify the quantity of dose (77).
• For example, the dispensing tip can be integrally formed with a lens. Therefore, allowing dose (77) to be observed in FIG. 6. This observation of dose (77) can be enhanced by utilizing a dose verification system. This dose verification system is summarized as a tube having the characteristic of two distinct different translucencies. The tube containing no liquid will have a first translucency [a]; and the tube containing a liquid will have a second translucency [b]. This change in translucency can be attained by the tube having a smooth outer surface; and a rough inner surface. Observing the tube without liquid produces an approximate translucent image; and observing the tube with liquid produces a transparent image. This change in translucency can be enhanced by having a black surface on the far side semi-annular surface of the tube. For this example, a dry tube appears to be light gray color; and the tube having liquid appears to be black color. Therefore, this distinct change in color confirms that the liquid is present in the tube.
• The present figures of the drawing show the tubes having a straight axis. The tubes utilized in the present prototypes have an arcuate shaped axis. This inherent arcuate shape is a result of the method of storage of the tube. i.e. bulk storage on a roll. The radius of this arc is estimated to be about 13 cm. NOTE: The initial velocity of the pbod in Experiment X is approximately parallel to a gravity vector. Initial velocity meaning the speed and direction immediately below outlet (25).
• Alternate liquids are capable to form a pbod. Including, water, i.e. AQUAFINA DRINKING WATER, (Bottling Group, LLC), TIMOLOL 0.5% or 0.3%, VISINE, CLEAR EYES.
• FIG. 6 depicts a particular dispensing position. And in light of the results of Experiments V, H, and L, there are clearly many alternate orientations of the dispenser, which will dispense a pbod. For example, For a 3 ul pbod, FIG. 6 can be rotated by any desired angle, and this rotated-view of FIG. 6 depicts a dispensing position.
• Experiments show that the most likely source of the overspray in Experiment X is residual liquid ejected immediately after the pbod is ejected. In light of the results of Experiment Q, it is contemplated that variations of prototype R29 will have no overspray. Also, variations of the viscosity of the liquid may eliminate the overspray.
• The present specification contains specific embodiments of apparatus utilized to form the present novel pbod systems, and these embodiments are presented for example only. And there are many alternate configurations, which are capable of forming the present novel pbod systems. Where these alternate configurations can be empericaly determined. For example, alternate attachment means, which do not form chemical reactions with liquid (50); alternate shapes; alternate dimensions; alternate material i.e. glass; alternate liquid (50); alternate viscosities of liquid (50); alternate gas (60) i.e. Hydrogen or Helium, motor fuel i.e. commonly referred to as nitrous oxide; alternate doses of liquid (50) i.e. 1 ul, 2 ul, or 3 ul including others; alternate ranges of dose (77); alternate quantity of dose (10); alternate collapsing speeds; alternate collapsing distance of the bottle walls; alternate rest positions i.e. a rest position where structure (22) is immersed in liquid (50); and alternate configurations of the bottle (40).
• The present specification contains specific embodiments of the present novel pbod systems, and these specific embodiments are provided for example only. Further, the present inventions are clearly pioneering discoveries, and the present inventions are not limited to the specific embodiments set forth herein, and only such limitations should be imposed as are set forth in the appended claims.

Claims (7)

1. (canceled)

2. (canceled)

3. A pbod system comprising:

a complete dose of gas composed essentially by a motive gas;

said dose of gas composing a plurality of balls;

said dose of gas is the complete dose of gas in one pbod.

4. A method of dispensing a liquid comprising the steps of:

a motive gas ejecting only one ball of liquid, where the quantity of said liquid is a dose; and said motive gas composing a complete dose of gas, where said complete dose of gas has the form of a plurality of balls; and said ball of liquid encloses said complete dose of gas.

5. The method of dispensing a liquid according to claim 4 wherein, said ball of liquid is ejected from an aperture; and said ball of liquid having a direction of motion, which is not in the direction of an Earth gravity vector; and said direction of motion exists on an interval between an instant after said ejection and an instant prior to said ball of liquid contacts a target.

6. An on demand method of dispensing 4 to 8 micro liters of liquid comprising the steps of: ejecting 4 to 8 micro liters of liquid on each selected instant, wherein said ejected liquid has the form of only one unitary body.

7. The on demand method of dispensing 4 to 8 micro liters of liquid according to claim 6 further including, a motive gas ejecting said liquid; and said motive gas composing a complete dose of gas; and said complete dose of gas having the form of a plurality of balls; and said ejected liquid encloses said complete dose of gas.

Images